Fampridine Sustained-release Tablets

Fampridine sustained-release tablets
Innovative drug to improve walking ability of adult patients with multiple sclerosis
In 2021, the world’s first and only innovative drug to improve walking ability of adult patients with multiple sclerosis, Fampridine sustained-release tablets, was approved for entry into China, filling the treatment gap in this field.
According to foreign clinical experience and extensive clinical research results of Fampridine sustained-release tablets, patients’ walking speed increased by an average of 25% after using Fampridine sustained-release tablets. Fampridine sustained-release tablets can be used alone or in combination with disease-modifying therapy (DMT) drugs, physical therapy and other symptomatic therapies, and Fampridine sustained-release tablets are suitable for all types of MS patients.